A study of AMT-130 in European Adults With Early Manifest Huntington Disease

The research company UniQure Biopharma B.V is conducting the clinical trial Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington Disease.

This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.

It is planned to include 15 participants.

Actual study start date is October 7, 2021. The researchers expect to complete the study by October 7, 2027.

The location of the study can be found here https://ichgcp.net/clinical-trials-registry/NCT05243017.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

A study of AMT-130 in European Adults With Early Manifest Huntington Disease

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe